Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
May 13 2020 - 5:00PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that three abstracts highlighting its drug candidate tipifarnib
have been accepted for presentation at the upcoming American
Society of Clinical Oncology (ASCO) Virtual Scientific Program, to
be held May 29-31, 2020.
“We are pleased to announce the presentation of three clinical
abstracts for tipifarnib, including an oral presentation
highlighting single-agent activity in multiple solid tumors with
HRAS mutations,” said Troy Wilson, Ph.D., J.D., President and Chief
Executive Officer of Kura Oncology. “In addition, the oral
presentation will feature compelling overall survival data from our
RUN-HN Phase 2 trial in head and neck squamous cell carcinoma
(HNSCC) patients with high HRAS mutant variant allele frequency,
and we look forward to sharing those data at ASCO later this
month.”
The three abstracts are listed below and are now available on
the ASCO meeting website at http://www.abstract.asco.org.
Preliminary activity of tipifarnib in tumors of the head
and neck, salivary gland and urothelial tract with HRAS
mutationsOral Abstract Session: Head and Neck
CancerAbstract: 6504
The AIM-HN and SEQ-HN Study: A Pivotal Study Evaluating
the Efficacy of Tipifarnib in Patients with Head and Neck Squamous
Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact
of HRAS Mutations on Response to First Line Systemic Therapies for
HNSCC (SEQ-HN)Poster Session: Head and Neck CancerAbstract
/ Poster: TPS6593 / 254
Tipifarnib, a farnesyltransferase inhibitor, for
metastatic urothelial carcinoma harboring HRAS
mutationsPoster Session: Genitourinary Cancer—Kidney and
BladderAbstract / Poster: 5086 / 155
Copies of the presentations will be available on Kura's website
at www.kuraoncology.com/pipeline/publications/ following
presentation at the meeting.
About Tipifarnib
Tipifarnib, is a potent, selective and orally bioavailable
inhibitor of farnesyl transferase in-licensed from Janssen in
December 2014. Previously, tipifarnib was studied in more than
5,000 cancer patients and showed compelling and durable anti-cancer
activity in certain patient subsets; however, no molecular
mechanism of action had been determined that could explain its
clinical activity across a range of solid tumor and hematologic
indications. Leveraging advances in next generation sequencing as
well as emerging information about cancer genetics and tumor
biology, the Company is seeking to identify those patients most
likely to benefit from tipifarnib. Tipifarnib has been granted Fast
Track designation by the U.S. Food and Drug Administration for the
treatment of patients with HRAS mutant HNSCC. Kura has received
multiple issued patents for tipifarnib, providing patent
exclusivity in the U.S. and foreign countries.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of two wholly
owned small molecule drug candidates that target cancer signaling
pathways where there is a strong scientific and clinical rationale
to improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s most advanced drug candidate is
tipifarnib, a potent, selective and orally bioavailable farnesyl
transferase inhibitor currently in a registration-directed trial in
patients with recurrent or metastatic HRAS mutant HNSCC. The
Company’s pipeline is also highlighted by KO-539, a potent and
selective inhibitor of the menin-KMT2A(MLL) protein-protein
interaction currently in a Phase 1/2A clinical trial in patients
with relapsed/refractory acute myeloid leukemia. For additional
information about Kura, please visit the Company’s website at
www.kuraoncology.com.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and therapeutic
potential of Kura’s product candidate tipifarnib. Factors that may
cause actual results to differ materially include the risk that
compounds that appeared promising in early research or clinical
trials do not demonstrate safety and/or efficacy in later
preclinical studies or clinical trials, the risk that Kura Oncology
may not obtain approval to market its product candidates,
uncertainties associated with performing clinical trials,
regulatory filings and applications, risks associated with reliance
on third parties to successfully conduct clinical trials, the risks
associated with reliance on outside financing to meet capital
requirements, and other risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. You are urged to consider
statements that include the words “may,” “will,” “would,” “could,”
“should,” “believes,” “estimates,” “projects,” “promise,”
“potential,” “expects,” “plans,” “anticipated,” “intends,”
“continues,” “designed,” “goal,” or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
company faces, please refer to the company’s periodic and other
filings with the Securities and Exchange Commission, which are
available at www.sec.gov. Such forward-looking statements are
current only as of the date they are made, and Kura Oncology
assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke ICR(858)
356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024